StockNow
CalendarLog in
Global Markets

AstraZeneca's (AZN LN) Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)

StockNow breaking-news AI analysis

CHMP recommended EU approval for AstraZeneca's Klygefa (gefurulimab) to treat adults with generalised myasthenia gravis.

1 stocks
AZNAstraZeneca PLC$166.69Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Commodities

Saudi Aramco reportedly tells Europe oil refiners that they will get no crude next month, sources suggest

Commodities

French President Macron says we are mulling options to release strategic energy reserves.

Politics

ECB President Lagarde says rates do not move in lockstep with energy prices, and that other factors play a role